4. Study on the values of HALP index in multiple myeloma
Main Article Content
Abstract
A correlational study was conducted on 72 patients diagnosed and treated for MM at Military Hospital 103 between January 2014 and January 2025 to study on the prognostic value of the HALP index and its correlation with treatment response in multiple myeloma (MM). Patients in the HALP index ≥ 30.08 group had a treatment response rate of 90.3%, higher than the 80.5% observed in the HALP index < 30.08 group. Patients with HALP index ≥ 30.08 had a 62.4% reduced risk of mortality compared to those with HALP index < 30.08. The mean progression-free survival (PFS) and overall survival (OS) for patients with HALP index ≥ 30.08 were 35.0 months and 64.2 months, respectively. These values were statistically higher than the PFS (17.9 months) and OS (27.6 months) in patients with HALP index < 30.08, with p-values of 0.048 and 0.006, respectively. The HALP index is associated with the levels of treatment response and may serve as an independent prognostic factor in patients with MM.
Article Details
Keywords
Multiple myeloma, HALP (Hemoglobin, Albumin, Lymphocyte, Platelet), Military Hospital 103
References
2. Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. Journal of clinical oncology. 2015; 33(26): 2863-2869.
3. Wongrakpanich S, George G, Chaiwatcharayut W, et al. The prognostic significance of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in patients with multiple myeloma. Journal of clinical laboratory analysis. 2016; 30(6): 1208-1213.
4. Solmaz Medeni S, Acar C, Olgun A, et al. Can Neutrophil-to-Lymphocyte Ratio, Monocyte-to-Lymphocyte Ratio, and Platelet-to-Lymphocyte Ratio at Day+ 100 be used as a prognostic marker in Multiple Myeloma patients with autologous transplantation? Clinical Transplantation. 2018; 32(9): e13359.
5. Chen X-L, Xue L, Wang W, et al. Prognostic significance of the combination of preoperative hemoglobin, albumin, lymphocyte and platelet in patients with gastric carcinoma: a retrospective cohort study. Oncotarget. 2015; 6(38): 41370.
6. Köşeci T, Seyyar M, Aydınalp Camadan Y, et al. HALP Score in Predicting Response to Treatment in Patients with Early-Stage Gastric Cancer: A Multi-Centred Retrospective Cohort Study. Medicina. 2024; 60(12): 2087.
7. Solmaz S, Uzun O, Sevindik OG, et al.. The effect of haemoglobin, albumin, lymphocyte and platelet score on the prognosis in patients with multiple myeloma. International Journal of Laboratory Hematology. 2023; 45(1): 13-19.
8. Vlatka P, Marko L, Stefan M, et al. The hemoglobin, albumin, lymphocyte, and platelet (HALP) score is a novel prognostic factor for patients with diffuse large B-cell lymphoma. Journal of Cancer Research and Therapeutics. 2022; 18(3): 725-732.
9. Jiang T, Sun H, Xue S, et al. Prognostic significance of hemoglobin, albumin, lymphocyte, and platelet (HALP) score in breast cancer: a propensity score-matching study. Cancer Cell International. 2024; 24(1): 230.
10. Patir P, Cerci K, Kurtoglu E. Prognostic Evaluation of Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score and Hematological Indices in Classic Hodgkin Lymphoma. International Journal of Laboratory Hematology. 2024;
11. Gursoy V, Sadri S, Kucukelyas HD, et al. HALP score as a novel prognostic factor for patients with myelodysplastic syndromes. Scientific Reports. 2024; 14(1): 13843.
12. Caro JJ, Salas M, Ward A, et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systematic, quantitative review. Cancer. 2001; 91(12): 2214-2221.
13. Don BR, Kaysen G. Poor nutritional status and inflammation: serum albumin: relationship to inflammation and nutrition. Wiley Online Library; 2004:432-437.